Aerie Pharmaceuticals reported $33.88M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Aerie Pharmaceuticals AERI:US USD 33.88M 5.73M
Alimera Sciences ALIM:US USD 9.86M 46K
Amarin AMRN:US USD 4.39M 82.51M
Bluebird Bio BLUE:US USD 33.4M 3.29M
Cara Therapeutics CARA:US USD 6.88M 658K
Coherus Biosciences CHRS:US USD 44.83M 6.44M
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
Horizon Pharma HZNP:US USD 397.56M 658K
Insmed INSM:US USD 75.58M 15.61M
Merk MRK:US USD 2.47B 13M
Mirati Therapeutics MRTX:US USD 60.8M 6.57M
Novartis NOVN:VX USD 3.4B 185M
Ophthotech OPHT:US USD 17.54M 1.44M
Pacira Pharmaceuticals PCRX:US USD 61.28M 3.72M
Regeneron Pharmaceuticals REGN:US USD 529.1M 52.8M
Revance Therapeutics RVNC:US USD 64.09M 17.91M
Supernus Pharmaceuticals SUPN:US USD 224.63M 124.15M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M
Valeant Pharmaceuticals VRX:CN USD 661M 15M
Zoetis ZTS:US USD 501M 28M